drugset
drugset / Trial / NCT03971916

A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

NCT03971916 ↗

Phase 1 Completed 24 enrolled Harbour BioMed (Guangzhou) Co. Ltd.
RandomizedSequentialSingle-blindBasic science

Summary

Trial Objective: To investigate the safety, tolerability, PK, and PD following single ascending doses of HBM9161 in healthy Chinese subjects.

Timeline

Start
2019-06-03
Primary completion
2019-11-06
Completion
2019-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Batoclimab Monoclonal antibody 340 mg Subcutaneous
Subject Batoclimab Monoclonal antibody 510 mg Subcutaneous
Subject Batoclimab Monoclonal antibody 680 mg Subcutaneous

Indications

No indication recorded.